索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]崔婧,贾方,孙建辉.生长分化因子-15与心血管疾病[J].国际心血管病杂志,2018,01:35-38.
点击复制

生长分化因子-15与心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年01期
页码:
35-38
栏目:
综述
出版日期:
2018-01-25

文章信息/Info

Title:
-
作者:
崔婧; 贾方; 孙建辉
213000 常州市第一人民医院心内科
Author(s):
-
关键词:
生长分化因子-15;  冠状动脉粥样硬化性心脏病;  心房颤动;  心力衰竭;  先天性心脏病
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2018.01.010
文献标识码:
-
摘要:
生长分化因子-15(GDF-15)是转化生长因子β超家族的远支成员。高水平GDF-15提示冠状动脉粥样硬化性心脏病(冠心病)患病风险较高。在冠心病、心房颤动、心力衰竭、先天性心脏病等心血管疾病中,高水平GDF-15提示预后较差。GDF-15可能通过参与动脉粥样硬化形成、保护梗死后心肌、抑制血栓形成等机制在心血管疾病的发生发展中发挥重要作用。
Abstract:
-

参考文献/References

[1] Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily[J]. Proc Natl Acad Sci U S A, 1997, 94(21):11514-11519.
[2] B?ttner M, Suter-Crazzolara C, Schober A, et al. Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1(GDF-15/MIC-1)in adult rat tissues[J]. Cell Tissue Res, 1999, 297(1):103-110.
[3] Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1[J]. Cytokine Growth Factor Rev, 2013, 24(4):373-384.
[4] Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study[J]. Lancet, 2002, 359(9324):2159-2163.
[5] Hagstr?m E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the Plato study[J]. Eur Heart J, 2016, 37(16):1325-1333.
[6] Martinez CH, Freeman CM, Nelson JD, et al. GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease[J]. Respir Res, 2017, 18(1):42.
[7] Wang X, Chen LL, Zhang Q. Increased serum level of growth differentiation factor 15(GDF-15)is associated with coronary artery disease[J]. Cardiovasc Ther, 2016, 34(3):138-143.
[8] Dallmeier D, Brenner H, Mons U, et al. Growth differentiation factor 15, its 12-month relative change, and risk of cardiovascular events and total mortality in patients with stable coronary heart disease: 10-year follow-up of the KAROLA study[J]. Clin Chem, 2016, 62(7):982-992.
[9] Hagstr?m E, Held C, Stewart RA, et al. Growth differentiation factor 15 predicts all-cause morbidity and mortality in stable coronary heart disease[J]. Clin Chem, 2017, 63(1):325-333.
[10] Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22[J]. Arterioscler Thromb Vasc Biol, 2011, 31(1):203-210.
[11] Zhang S, Dai D, Wang X, et al. Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis[J]. BMC Cardiovasc Disord, 2016, 16:82.
[12] Eggers KM, Kempf T, Venge P, et al. Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events(GRACE)risk score is enhanced by selected nonnecrosis biomarkers[J]. Am Heart J, 2010, 160(1):88-94.
[13] Wallentin L, Lindhagen L, ?rnstr?m E, et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome(FRISC-Ⅱ): 15 year follow-up of a prospective, randomised, multicentre study[J]. Lancet, 2016, 388(154):1903-1911.
[14] Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction[J]. Eur J Heart Fail, 2016, 18(1):81-88.
[15] Hijazi Z, Oldgren J, Lindb?ck J, et al. The novel biomarker-based ABC(age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study[J]. Lancet, 2016, 387(135):2302-2311.
[16] Wang T, Liu J, Mcdonald C, et al. GDF15 is a heart-derived hormone that regulates body growth[J]. EMBO Mol Med, 2017, 9(8):1150-1164.
[17] Baggen VJ, Van Den Bosch AE, Eindhoven JA, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide, troponin-T, and growth-differentiation factor 15 in adult congenital heart disease[J]. Circulation, 2017, 135(3):264-279.
[18] Johnen H, Kuffner T, Brown DA, et al. Increased expression of the TGF-b superfamily cytokine MIC-1/GDF15 protects ApoE(-/-)mice from the development of atherosclerosis[J]. Cardiovasc Pathol, 2012, 21(6):499-505.
[19] Bonaterra GA, Zügel S, Thogersen J, et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury[J]. J Am Heart Assoc, 2012, 1(6):e002550.
[20] De Jager SC, Bermúdez B, Bot I, et al. Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis[J]. J Exp Med, 2011, 208(2):217-225.
[21] Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury[J]. Circ Res, 2006, 98(3):351-360.
[22] Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice[J]. Nat Med, 2011, 17(5):581-588.
[23] Rossaint J, Vestweber D, Zarbock A. GDF-15 prevents platelet integrin activation and thrombus formation[J]. J Thromb Haemost, 2013, 11(2):335-344.

备注/Memo

备注/Memo:
通信作者:孙建辉,Email:sunjianh@sohu.com
更新日期/Last Update: 2018-04-01